Shisi Pharmaceutical Group (02005) has obtained drug production registration approval for cimetidine injection (2ml: 0.2g)

Zhitong Finance App News, Shisi Pharmaceutical Group (02005) announced that the group has obtained drug production registration approval from the China National Drug Administration for cimetidine injection (2ml: 0.2g), which is a Class 3 chemical drug, and is deemed to have passed the consistency evaluation. Cimetidine injections are mainly used to treat gastrointestinal ulcers.

Furthermore, the group has obtained approval from the State Drug Administration for the production of acetylcysteine solution for inhalation (3ml: 0.3 g), which is a Class 4 chemical, and is deemed to have passed the consistency evaluation. Acetylcysteine solution for inhalation is mainly used to treat respiratory diseases with excessive thick mucous secretions such as acute bronchitis, chronic bronchitis and worsening of the condition, emphysema, sticky matter obstruction, and bronchiectasis. This product complements the Group's expectorant nebulizer variety and enriches the nebulizer inhalation treatment plan for respiratory diseases.